Prostate Cancer

Researchers search for hereditary prostate cancer in genome study

Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease. The researchers analyzed the Nashville Familial Prostate Cancer Study (NFPCS), in an investigation comparing men with prostate cancer, each from a separate family with a strong history of the disease, to screened men without a personal or family history of prostate cancer. They analyzed haplotypes at a location of chromosome 8 which has been tied to the origin of prostate and numerous additional cancers. The study, published March 23 in Nature Communications, explains roughly 9% of prostate cancer heritability. One mutation increased risk as much as 22-fold. [...]

2020-04-06T13:39:50-07:00April 6th, 2020|

Pilot study repurposes antidepressant to fight prostate cancer

An antidepressant in use for decades, repurposed to fight prostate cancer, shows promise in helping patients whose disease has returned following surgery or radiation, a pilot study at USC shows. The drug -- an MAO inhibitor called phenelzine -- represents a potential new treatment direction with fewer side effects for men with recurrent prostate cancer, researchers said. "To our knowledge, this study is the first clinical trial of an MAO inhibitor in cancer patients," said senior author Jean Shih, a University Professor in USC's School of Pharmacy who has studied the enzyme MAO, or monoamine oxidase, for four decades. The research appears in the journal Prostate Cancer and Prostatic Diseases. "If our findings are confirmed, this could be part of a new avenue [...]

2020-03-10T12:53:09-07:00March 10th, 2020|

Study examines prostate cancer treatment decisions

5-year study examines common prostate cancer treatment options (See new HIFU study results at bottom of this article.) A five-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care. The CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation for Localized Prostate Cancer) study, coordinated by Vanderbilt University Medical Center, is a multi-site research study conducting long-term followup on men who were diagnosed with localized prostate cancer between 2011 and 2012. The five-year results published in JAMA, with lead author Karen Hoffman, MD, MPH, from MD Anderson, provide evidence on outcomes with [...]

2020-02-18T10:25:52-08:00February 18th, 2020|

HIFU for prostate cancer shows excellent results in new study

Kia Michel, MD The 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer in Washington, D.C. featured Dr. Kia Michel, of Beverly Hills, Calif., who spoke on the outstanding data on focal HIFU outcomes for localized prostate cancer. Dr. Michel presented a poster on near-term HIFU outcomes based on his experience treating men with localized prostate cancer with the Sonablate. He presented that 78 men with prostate cancer underwent HIFU and were tracked post-treatment and re-biopsied at 12 months. He concluded that there was excellent disease control after HIFU ablation and most men were able to retain full urinary continence and erectile function levels equal to those pre-HIFU treatment. “I feel like it is important to report on [...]

2020-02-10T14:04:05-08:00February 10th, 2020|

Study reveals that being active has significant impact on prostate cancer risk

Prostate cancer is the number one cancer risk for men, as well as the No. 2 cancer killer behind lung cancer in the US, yet we still don't know all of its causes. The largest ever study to use genetics as a measurement for physical activity to look at its effect on prostate cancer, reveals that being more active reduces the risk of prostate cancer. Over 140,000 men were included in the study, of which, 80,000 had prostate cancer. This new study, published in the International Journal of Epidemiology in December, was led by the University of Bristol and co-funded by World Cancer Research Fund (WCRF) and Cancer Research UK (CRUK). It found that people with the variation in their DNA sequence that [...]

2020-02-04T13:01:18-08:00February 4th, 2020|

Benefits of HIFU technology revealed in 3 studies and reports

Three articles have appeared in press since June 2018 based on clinical trials undertaken in the U.K., that highlight the medium to long-term durability of Sonablate treatments in the control of prostate cancer when used in the partial gland ablation setting.1,2,3  Across the three articles and a total of more than 1,800 men, salvage free survival (no need for a whole gland or systemic treatment) was greater than 90% out as far as 60 months.  This excellent disease control was accompanied by a pad-free incontinence rate of greater than 98% and maintenance of erectile function in more than 80% of men. An additional article based on Canadian experience produced roughly similar results. 14 Dr. Mark Carol, CEO of SonaCare Medical writes,“While few will [...]

2020-01-27T13:26:59-08:00January 27th, 2020|

Understanding Prostate Screening & Treatment Options

For some types of cancer, screening can help find cancers at an early stage, when they are more likely to be easier to treat. According to the American Cancer Society, prostate cancer can often be found before symptoms arise by testing the amount of prostate-specific antigen (PSA) in a man’s blood. Another way to find prostate cancer is the digital rectal exam (DRE), in which the doctor puts a gloved, lubricated finger into the rectum to feel the prostate gland. If the results of either one of these tests are abnormal, further testing is often done to see if a man has cancer. If prostate cancer is found as a result of screening with the PSA test or DRE, it will probably be at [...]

2019-12-03T10:47:39-08:00December 3rd, 2019|

A Typical HIFU Procedure Day

Wake up, get ready, and head to the treatment facility. Patients will need to complete their bowel prep per their MD’s instruction. This is comparable to a prostate biopsy bowel prep. 6 am – 7 am | Arrive at treatment facility, be greeted by staff, and enter procedure preparation area. Patients will typically be asked to arrive at the treatment facility at least an hour before the procedure. 7 am – 10 am | Sonablate HIFU Procedure A typical HIFU procedure lasts between 2-4 hours (depending on the size of the prostate) and is either done under general anesthesia or an epidural and IV sedation. During the procedure a catheter will be put in place to help with urination, and will stay in [...]

2019-11-19T09:50:33-08:00November 12th, 2019|

Researchers identify new factors that may help reduce prostate cancer risk

Men with higher levels of 'free' testosterone and a growth hormone in their blood are more likely to be diagnosed with prostate cancer, according to research presented at the 2019 NCRI Cancer Conference. Other factors such as older age, ethnicity and a family history of the disease are already known to increase a man's risk of developing prostate cancer. However, the new study of more than 200,000 men is one of the first to show strong evidence of two factors that could possibly be modified to reduce prostate cancer risk. The research was led by Dr Ruth Travis, an Associate Professor, and Ellie Watts, a Research Fellow, both based at the Nuffield Department of Population Health, University of Oxford, UK. Dr Travis said: [...]

2019-11-05T08:21:24-08:00November 5th, 2019|

Urine test could offer early detection of prostate cancer

A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection. Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries [...]

2019-10-08T10:17:47-07:00October 8th, 2019|